Clinical Trial Detail

NCT ID NCT03606174
Title Sitravatinib and Nivolumab in Urothelial Carcinoma Study
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mirati Therapeutics Inc.
Indications

transitional cell carcinoma

Therapies

MGCD516 + Nivolumab

Age Groups: senior adult

No variant requirements are available.